These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9593221)

  • 61. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.
    Dean BB; Siddique RM; Yamashita BD; Bhattacharjya AS; Ofman JJ
    Am J Health Syst Pharm; 2001 Jul; 58(14):1338-46. PubMed ID: 11471482
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors.
    Le GH; Schaefer MG; Plowman BK; Morreale AP; Delattre M; Okino L; Felicio L
    Am J Health Syst Pharm; 2003 Jul; 60(13):1343-5. PubMed ID: 12901036
    [No Abstract]   [Full Text] [Related]  

  • 63. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
    Park SH
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
    [No Abstract]   [Full Text] [Related]  

  • 64. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.
    Morii M; Takata H; Fujisaki H; Takeguchi N
    Biochem Pharmacol; 1990 Feb; 39(4):661-7. PubMed ID: 2154989
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
    Sachs G; Shin JM; Pratha V; Hogan D
    Drugs Today (Barc); 2003 Mar; 39 Suppl A():11-4. PubMed ID: 12712216
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Microtubule modulation of biliary excretion of endogenous and exogenous hepatic lysosomal constituents.
    Sewell RB; Barham SS; Zinsmeister AR; LaRusso NF
    Am J Physiol; 1984 Jan; 246(1 Pt 1):G8-15. PubMed ID: 6696071
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].
    Khavkin AI; Zhikhareva NS; Rachkova NS; Babaian ML; Volynets GV; Khanakaeva ZK
    Eksp Klin Gastroenterol; 2004; (2):53-6. PubMed ID: 15462323
    [No Abstract]   [Full Text] [Related]  

  • 68. Transfer and distribution of amoxicillin in the rat gastric mucosa and gastric juice and the effects of rabeprazole.
    Zheng HL; Hu YM; Bao JJ; Xu JM
    Acta Pharmacol Sin; 2010 Apr; 31(4):501-8. PubMed ID: 20305682
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
    Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
    Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Comparative study of proton pump inhibitors].
    Herszényi L; Tulassay Z
    Orv Hetil; 2001 Sep; 142(36):1953-61. PubMed ID: 11680100
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Cause and prevention of nocturnal gastric acid breakthrough].
    Adachi K; Kinoshita Y
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():779-83. PubMed ID: 11979888
    [No Abstract]   [Full Text] [Related]  

  • 72. The effects of benzo(a)pyrene on rat liver lysosomes.
    Carević M; Carević O
    Toxicol Lett; 1982 Jan; 10(1):41-9. PubMed ID: 6805101
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New fluorescent probes E3810 and methoxy E3810 for determining distributions of the apical membrane and the acidic compartment of gastric acid secreting cells.
    Takeguchi N; Yamanouchi T; Sakai H; Morii M
    Jpn J Physiol; 1992; 42(1):75-88. PubMed ID: 1320706
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased hepatic lysosomal activity in biliary cirrhosis originates from hepatocytes rather than from macrophages.
    Dufour JF; Zimmermann A; Reichen J
    J Hepatol; 1994 Apr; 20(4):524-30. PubMed ID: 8051392
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rabeprazole: quest for the best PPI.
    Sugano K
    J Gastroenterol; 2002; 37(3):233-4. PubMed ID: 11931540
    [No Abstract]   [Full Text] [Related]  

  • 76. Temporal changes of acid phosphatase, arylsulphatase, beta-galactosidase and beta-N-acetyl-D-glucosaminidase activities in subcellular fractions of rat liver.
    Wójczyk B; Lityńska A; Kalisz A
    Chronobiol Int; 1986; 3(1):29-37. PubMed ID: 3119233
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Activity and localisation of the lysosomal marker enzymes acid phosphatase, N-acetyl-beta-D-glucosaminidase, and beta-galactosidase in the earthworms Eisenia fetida and E. veneta.
    Hønsi TG; Stenersen J
    Comp Biochem Physiol B Biochem Mol Biol; 2000 Mar; 125(3):429-37. PubMed ID: 10818277
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of antrectomy and drug-induced achlorhydria on urinary excretion of N-terminal big gastrin immunoreactivity in rats.
    Miyazaki Y; Shinomura Y; Yasunaga Y; Higashimoto Y; Kanayama S; Aoki T; Okuda Y; Narita T; Miwa K; Miyazaki I
    Regul Pept; 1993 Nov; 49(1):49-56. PubMed ID: 8278633
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Proton pump inhibitors--differences emerge in hepatic metabolism.
    McColl KE; Kennerley P
    Dig Liver Dis; 2002 Jul; 34(7):461-7. PubMed ID: 12236477
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Determination of a new H(+)-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography.
    Nakai H; Shimamura Y; Kanazawa T; Yasuda S; Kayano M
    J Chromatogr B Biomed Appl; 1994 Oct; 660(1):211-20. PubMed ID: 7858718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.